Collaborations

National

  • Prof. Fritz Aberger, University Salzburg, skin cancer and hedgehog signaling
  • Prof. Thomas Decker, MFPL Vienna, STAT1 in melanoma
  • Prof. Reinhold Erben, University of Veterinary Medicine, Vienna, Ewing´s sarcoma
  • Prof. Heinrich Kovar, CCRI Vienna, Ewing´s sarcoma
  • Dr. Robert Kralovics, CeMM, MPN mouse models
  • Prof. Wolfgang Mikulits, Medical University Vienna, liver cancer
  • Prof. Mathias Müller, University of Veterinary Medicine, Vienna, Tyk2 and transgenesis
  • Prof. Thomas Rülicke, University of Veterinary Medicine, Vienna, mouse models
  • Prof. Veronika Sexl, University of Veterinary Medicine, Vienna, JAK-STAT in cancer, CML resistance mechanisms and CDK6
  • Prof. B. Strobl, University of Veterinary Medicine, Vienna, STAT1 signaling
  • Prof. Michael Trauner, Medical University Vienna, metabolism and liver cancer
  • Prof. Peter Valent, Medical University Vienna, MPN and leukemia

International

  • Prof. K.D. Bunting, Emory University, Atlanta, USA, interference with inhibitors of the PI3K-AKT-mTOR cascade in neoplastic cells
  • Prof. S. Constantinescu, Ludwig Cancer Institute, Bruessel, Belgium, p53 mutations and MPN
  • Prof. M. Deininger, Utah Huntsman CI, Salt Lake City, USA, STAT3/5 in the evolution and progression of CML and targeting them
  • Prof. K. Friedrich, Institute for Biochemistry, Friedrich Schiller University Jena, Jena, Germany, colorectal cancer
  • Prof. B. Groner, Georg-Speyer-Haus, Frankfurt, Germany, oncogenic STAT3/5
  • Prof. P. Gunning, University Toronto, SH2 domain inhibitors
  • Prof. X. Han, Cincinnati Children's Hospital Medical Center, Cincinnati, USA, cytokine signaling in the GI tract for inflammatory and neoplastic disease
  • Prof. M. Heim and Prof. L. Terracciano, University Hospital Basel, Basel, Switzerland, liver cancer and metabolism
  • Prof. L. Hennighausen and Prof. J. O´Shea, NIH, Washington, USA, immunity, mouse models of STAT function
  • Prof. F. Gouilleux, Université Rabelais, Tours, France, STAT5 in leukemogenesis and PI3K-AKT-mTOR signaling
  • Prof. AT. Look, Dana Farber, Boston, USA, T-cell leukemia and mutated JAK kinases
  • Prof. G. Müller-Newen, RWTH Aachen, Deutschland, STAT5 shuttling in CML and AML
  • Prof. W. Priebe, MD Anderson Cancer Center, USA, inhibitors of transcription factors
  • Prof. W. Tse, James Graham Brown Cancer Center, Louisville, Kentucky, USA, AF1q in MetastasisAF1q in breast cancer metastasis
  • Prof. J. Tuckermann, University Ulm, Ulm, Germany, GR-STAT5 in hematopoietic cells and for metabolic control
  • Prof. K.U. Wagner, Eppley Institute for Research in Cancer and Allied Diseases, Omaha, USA, JAK2-STAT5 signaling and transgenic mouse models

To top